FUTURE ONCOLOGY
Volume 5 #10/11 July 30, 2000
State-of-the-Art in the Management of Cancer
LUNG CANCER-PART VI
Novel Agents/Formulations in
development
Novel
Chemotherapeutics
Spindle Poisons
Anhydrovinblastine
BMS-184476
Maytansinoid
immunoconjugates
PG-TXL
Taxoprexin
T67
Topoisomerase I Inhibitors
Exatecan
mesylate
TAS-103
XR5000
Antifolates
Alimta
S-1
Nucleosides
Decitabine
FMdC
Platinum-based Agents
Nedaplatin
Oxaliplatin
Satraplatin
Other Agents
Bendamustin
CHS
828
CI-994
Irofulven
Temozolomide
Tirapazamine
Novel
Formulations And Drug Delivery Approaches
Lipid Formulations
Onco
TCS
Liposome-encapsulated
paclitaxel (LEP)
Aerosol Delivery
Aerosol
doxorubicin
Aerosol
retinoids
Aerosolized
GM-CSF
Inhaled RFS 2000
Angiogenesis
Inhibitors
Matrix Metalloproteinase Inhibitors (MMPI)
BMS-275291
Marimastat
Neovastat
Prinomastat
Angiostatin and Endostatin
Squalamine
VEGF Antagonists
Angiozyme
rhuMAb-VEGF
Semoxind
Other Agents
BN-50730
Regulation
Cell Cycle Regulation
Flavopiridol
UCN-01
Approaches Targeting the Epidermal Growth Factor Receptor (EGFr)
ABX-EGF
Trastuzumab
ZD
1839
Farnesyl Tranferase Inhibitors (FTI)
R115777
SCH
66336
Approaches Targeting p53
rAd/p53
RPR/INGN
201
ONYX-015
Agents Targeting Other Markers
G3139
ISIS
3521
Immunotherapy/Vaccines
Cytokine-producing Tumor Vaccines
SRL172
Vaccines Against CEA-expressing Tumors
Anti-CEA
antibodies
Recombinant
viruses expressing CEA protein or peptides
Dendritic
cells expressing CEA
Vaccines Against Ganglioside-expressing Tumors
Fucosyl-GM1-keyhole
limpet hemocyanin (KLH) conjugate vaccine
Mitumomab
(BEC2)
Vaccines Against
MUC-1-expressing Tumors
BLP-25
Vaccines Against Tumors Expressing HER2
HER2
Peptide Vaccine
Radiation
Therapy
Radioimmunoconjugates
Pantacea
Radiosensitizers
KIN-806
Motexafin
gadolinium
RSR-13
Proton Beam Therapy
Chemoprevention
Vitamins
Celecoxib
Exisulind
Retinoids
Thymalfasin
|